2024年6月最新影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Journal for ImmunoTherapy of Cancer J IMMUNOTHER CANCER （此期刊被最新的JCR期刊SCIE收录） LetPub评分 8.5
53人评分
我要评分
声誉 9.4 影响力 8.0 速度 7.0 | |||||||||||||||||||||||||||||||||||||
| 期刊ISSN | 2051-1426 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||||||||||||||
| 2023-2024最新影响因子 （数据来源于搜索引擎） | 10.3 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||||||||||
| 实时影响因子 | 截止2024年10月29日：7.557 | |||||||||||||||||||||||||||||||||||||
| 2023-2024自引率 | 2.90%点击查看自引率趋势图 | |||||||||||||||||||||||||||||||||||||
| 五年影响因子 | 11.6 | |||||||||||||||||||||||||||||||||||||
| JCI期刊引文指标 | 2.01 | |||||||||||||||||||||||||||||||||||||
| h-index | 36 | |||||||||||||||||||||||||||||||||||||
| CiteScore （ 2024年最新版） |
| |||||||||||||||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||||||||||||||
| 期刊官方网站 | https://www.springer.com/journal/40425 | |||||||||||||||||||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/JITC | |||||||||||||||||||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Journal for ImmunoTherapy of Cancer的语言要求，还能让Journal for ImmunoTherapy of Cancer编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Journal for ImmunoTherapy of Cancer编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢（2篇） 。
提交文稿 | |||||||||||||||||||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ USD2972; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：tumour immunology、cancer immunotherapy、immunotherapy biomarkers 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||||||||||||||||||
| 通讯方式 | BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND, WC1H 9JR | |||||||||||||||||||||||||||||||||||||
| 出版商 | BioMed Central | |||||||||||||||||||||||||||||||||||||
| 涉及的研究方向 | Biochemistry, Genetics and Molecular Biology-Molecular Medicine | |||||||||||||||||||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||||||||||||||||||
| 出版年份 | 2013 | |||||||||||||||||||||||||||||||||||||
| 年文章数 | 417点击查看年文章数趋势图 | |||||||||||||||||||||||||||||||||||||
| Gold OA文章占比 | 98.98% | |||||||||||||||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 93.76% | |||||||||||||||||||||||||||||||||||||
| WOS期刊SCI分区 （ 2023-2024年最新版） | WOS分区等级：1区
| |||||||||||||||||||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2023年12月最新升级版） | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2022年12月升级版） |
| |||||||||||||||||||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2021年12月旧的升级版） |
| |||||||||||||||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2051-1426%5BISSN%5D | |||||||||||||||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 18 Weeks | |||||||||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ USD2972; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Journal for ImmunoTherapy of Cancer顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation Author: Zhang, Biying; Li, Jiao; Hua, Qingling; Wang, Haihong; Xu, Guojie; Chen, Jiayuan; Zhu, Ying; Li, Ruiqi; Liang, Qing; Wang, Lanqing; Jin, Min; Tang, Jing; Lin, Zhenyu; Zhao, Lei; Zhang, Dejun; Yu, Dandan; Ren, Jinghua; Zhang, Tao Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-005592 PubMed DOI |
| 2. | Novel combination strategy of high intensity focused ultrasound (HIFU) and checkpoint blockade boosted by bioinspired and oxygen-supplied nanoprobe for multimodal imaging-guided cancer therapy Author: Tang, Rui; He, Hongye; Lin, Xiaohong; Wu, Nianhong; Wan, Li; Chen, Qiaoqi; Hu, Yaqin; Cheng, Chen; Cao, Yuting; Guo, Xun; Zhou, Ying; Xiong, Xialin; Zheng, Min; Wang, Qi; Li, Faqi; Zhou, Yang; Li, Pan Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-006226 PubMed DOI |
| 3. | Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy Author: Shi, Lin; Lu, Jinying; Zhong, Da; Song, Meijuan; Liu, Jian; You, Wenhua; Li, Wen-Hui; Lin, Lin; Shi, Dongyan; Chen, Yun Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-005902 PubMed DOI |
| 4. | STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer Author: Ding, Liya; Wang, Qiwei; Martincuks, Antons; Kearns, Michael J.; Jiang, Tao; Lin, Ziying; Cheng, Xin; Qian, Changli; Xie, Shaozhen; Kim, Hye-Jung; Launonen, Inga-Maria; Faerkkilae, Anniina; Roberts, Thomas M.; Freeman, Gordon J.; Liu, Joyce F.; Konstantinopoulos, Panagiotis A.; Matulonis, Ursula; Yu, Hua; Zhao, Jean J. Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-005627 PubMed DOI |
| 5. | Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy Author: Dai, Jie; Bai, Xue; Gao, Xuan; Tang, Lirui; Chen, Yu; Sun, Linzi; Wei, Xiaoting; Li, Caili; Qi, Zhonghui; Kong, Yan; Cui, Chuanliang; Chi, Zhihong; Sheng, Xinan; Xu, Zelong; Lian, Bin; Li, Siming; Yan, Xieqiao; Tang, Bixia; Zhou, Li; Wang, Xuan; Xia, Xuefeng; Guo, Jun; Mao, Lili; Si, Lu Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-005937 PubMed DOI |
| 6. | New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors Author: Bamias, Aristotelis; Merseburger, Axel; Loriot, Yohann; James, Nicholas; Choy, Ernest; Castellano, Daniel; Lopez-Rios, F.; Calabro, Fabio; Kramer, Mario; de Velasco, Guillermo; Zakopoulou, Roubini; Tzannis, Kimon; Sternberg, Cora N. Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-005977 PubMed DOI |
| 7. | Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers Author: Ba, Hongping; Dai, Zigang; Zhang, Zunyue; Zhang, Peng; Yin, Bingjiao; Wang, Jing; Li, Zhuoya; Zhou, Xiaoxi Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2021-003837 PubMed DOI |
| 8. | Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases Author: Zhang, Chong; Wang, Xiang-Yu; Zuo, Jie-Liang; Wang, Xue-Fu; Feng, Xiao-Wen; Zhang, Bo; Li, Yi-Tong; Yi, Chen-He; Zhang, Peng; Ma, Xiao-Chen; Chen, Zhen-Mei; Ma, Yue; Han, Jia-Hao; Tao, Bao-Rui; Zhang, Rui; Wang, Tian-Qi; Tong, Li; Gu, Wang; Wang, Si-Yu; Zheng, Xiao-Fei; Yuan, Wen-Kang; Kan, Zi-Jie; Fan, Jie; Hu, Xiang-Yang; Li, Jun; Zhang, Chao; Chen, Jin-Hong Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 2, pp. -. DOI: 10.1136/jitc-2022-006425 PubMed DOI |
| 9. | T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma Author: Wang, Xiaobin; Zhang, Qiaoyun; Zhou, Jingwen; Xiao, Zecong; Liu, Jianxin; Deng, Shaohui; Hong, Xiaoyang; Huang, Wensou; Cai, Mingyue; Guo, Yongjian; Huang, Jingjun; Wang, Yong; Lin, Liteng; Zhu, Kangshun Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 2, pp. -. DOI: 10.1136/jitc-2022-006493 PubMed DOI |
| 10. | Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability Author: Tang, Jianghui; Sheng, Jianpeng; Zhang, Qi; Ji, Yongtao; Wang, Xun; Zhang, Junlei; Wu, Jiangchao; Song, Jinyuan; Bai, Xueli; Liang, Tingbo Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 2, pp. -. DOI: 10.1136/jitc-2022-006119 PubMed DOI |
|
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
